Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.

Try Elite for Free

ProKidney

Contributing Author

Recent Articles by ProKidney

Aug-10	ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights PROK GlobeNewswire
Jun-02	ProKidney Appoints Kenneth Locke as Chief Technical Officer PROK GlobeNewswire
May-15	ProKidney Reports First Quarter 2026 Financial Results and Business Highlights PROK GlobeNewswire
Mar-25	ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer PROK GlobeNewswire
Mar-18	ProKidney Reports Full Year 2025 Financial Results and Business Highlights PROK PROK -6.25% GlobeNewswire
Jan-06	ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference PROK +5.14% GlobeNewswire
Nov-10	ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates PROK -6.57% GlobeNewswire
Nov-06	ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025 PROK GlobeNewswire
Oct-29	ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference PROK GlobeNewswire
Oct-20	ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2025 PROK +10.77% GlobeNewswire
Aug-27	ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference PROK GlobeNewswire
Aug-12	ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates PROK PROK +5.80% GlobeNewswire
Jul-15	ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel PROK -8.67% GlobeNewswire
Jul-09	ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference PROK +16.35% GlobeNewswire
Jul-08	ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes PROK +515.00% GlobeNewswire
Jul-01	ProKidney Corp. Completes Domestication from the Cayman Islands to Delaware PROK GlobeNewswire
May-12	ProKidney Reports First Quarter 2025 Financial Results and Business Highlights PROK PROK +15.79% GlobeNewswire

Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)